Skip directly to page options Skip directly to A-Z link

Volume 23, Number 11—November 2017

Dispatch

Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru

Ruvandhi R. Nathavitharana1Comments to Author , Cynthia X. Shi1, Leonid Chindelevitch, Roger Calderon, Zibiao Zhang, Jerome T. Galea, Carmen Contreras, Rosa Yataco, Leonid Lecca, Mercedes C. Becerra, Megan B. Murray, and Ted Cohen
Author affiliations: Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA, and Imperial College London, London, UK (R.R. Nathavitharana); Yale School of Public Health, New Haven, Connecticut, USA (C.X. Shi, T. Cohen); Simon Fraser University, Burnaby, British Columbia, Canada (L. Chindelevitch); Socios En Salud Sucursal Peru, Lima, Peru (R. Calderon, J.T. Galea, C. Contreras, R. Yataco, L. Lecca); Harvard Medical School, Boston (Z. Zhang, J.T. Galea, L. Lecca, M.C. Becerra, M.B. Murray)

Main Article

Table 2

Factors associated with clonal and polyclonal Mycobacterium tuberculosis infection among patients with pulmonary TB, Lima, Peru, September 2009–August 2012*

Characteristic Clonal aOR (95% CI), n = 115 p value Polyclonal aOR (95% CI), n = 161 p value
Age, y
15–24 Referent Referent
25–34 1.21 (0.75–1.96) 0.44 1.40 (0.93–2.11) 0.11
35–44 1.16 (0.64–2.11) 0.62 1.42 (0.87–2.31) 0.16
>45
 1.33 (0.79–2.23)
 0.29
 1.22 (0.77–1.95)
 0.40
Male sex
 0.93 (0.63–1.38)
 0.72
 1.10 (0.78–1.55)
 0.59
Previous TB 0.82 (0.48–1.37) 0.45 1.27 (0.86–1.86) 0.23
Previous INH receipt 1.51 (0.54–4.27) 0.44 1.84 (0.82–4.15) 0.14
HIV infection 0.99 (0.35–2.78) 0.98 1.12 (0.50–2.49) 0.79
≥1 chronic disease
 0.90 (0.55–1.46)
 0.66
 0.97 (0.64–1.46)
 0.88
Hospitalized
 1.01 (0.58–1.75)
 0.97
 0.98 (0.61–1.57)
 0.93
Resistance pattern
Pansensitive Referent Referent
INH or RIF resistance 1.11 (0.58–2.13) 0.76 1.38 (0.81–2.37) 0.24
Multidrug resistance 1.24 (0.70–2.22) 0.46 1.66 (1.05–2.62) 0.03
Other 1.34 (0.77–2.33) 0.31 1.97 (1.27–3.06) 0.002

*Results of multivariable regression analysis using classifier of tandem repeats method. aOR, adjusted odds ratio; INH, isoniazid; RIF, rifampin; TB, tuberculosis.

Main Article

1These authors contributed equally to this article.

Page created: October 17, 2017
Page updated: October 17, 2017
Page reviewed: October 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external